- Next-generation MOP mRNA platform: CTx develops vaccines and therapeutics powered by its proprietary Multi-Organ Protection (MOP) technology, supported by broad patents.
- Precise control: MOP finely regulates mRNA translation and enables tissue-specific protein expression, enhancing safety and biodistribution (heart, liver, kidneys… protections).
- Flexible design: The platform applies to both antigens and molecular adjuvants, allowing modular vaccine design across multiple indications.
- Adjuvant innovation: Expanding portfolio of mRNA-encoded cytokine adjuvants (e.g., IL-12, GM-CSF, IL-21) to boost magnitude, quality, and persistence of immune responses particularly for vulnerable population.
- Pipeline & validation: Programs across infectious diseases (COVID/Flu, RSV, shingles, C. difficile) and immunology and oncology (CAR-T).